Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey
Language English Country Netherlands Media print-electronic
Document type Journal Article
PubMed
30172478
DOI
10.1016/j.ijcard.2018.06.104
PII: S0167-5273(18)32931-0
Knihovny.cz E-resources
- Keywords
- Coronary heart disease, Cost-effectiveness, EUROASPIRE, Guidelines, Secondary prevention,
- MeSH
- Cost-Benefit Analysis methods standards MeSH
- Guideline Adherence economics standards MeSH
- Coronary Disease economics epidemiology prevention & control MeSH
- Middle Aged MeSH
- Humans MeSH
- Decision Trees * MeSH
- Aged MeSH
- Practice Guidelines as Topic standards MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Europe epidemiology MeSH
BACKGROUND: This study aims to assess the cost-effectiveness of optimized guideline adherence in patients with a history of coronary heart disease. METHODS: An individual-based decision tree model was developed using the SMART risk score tool which estimates the 10-year risk for recurrent vascular events in patients with manifest cardiovascular disease (CVD). Analyses were based on the EUROASPIRE IV survey. Outcomes were expressed as an incremental cost-effectiveness ratio (ICER). RESULTS: Data from 4663 patients from 13 European countries were included in the analyses. The mean estimated 10-year risk for a recurrent vascular event decreased from 20.13% to 18.61% after optimized guideline adherence. Overall, an ICER of 52,968€/QALY was calculated. The ICER lowered to 29,093€/QALY when only considering high-risk patients (≥20%) with decreasing ICERs in higher risk patients. Also, a dose-response relationship was seen with lower ICERs in older patients and in those patients with higher risk reductions. A less stringent LDL target (<2.5 mmol/L vs. <1.8 mmol/L) lowered the ICER to 32,591€/QALY and intensifying cholesterol treatment in high-risk patients (≥20%) instead of high-cholesterol patients lowered the ICER to 28,064€/QALY. An alternative method, applying risk reductions to the CVD events instead of applying risk reductions to the risk factors lowered the ICER to 31,509€/QALY. CONCLUSION: Depending on the method used better or worse ICERs were found. In addition, optimized guidelines adherence is more cost-effective in higher risk patients, in patients with higher risk reductions and when using a less strict LDL-C target. Current analyses advice to maximize guidelines adherence in particular patient subgroups.
Cardiology Unit Department of Medicine Solna Karolinska Institutet Stockholm Sweden
Clinic for Internal Medicine Intermedica Nis Serbia
Department of Cardiology National Heart Hospital Sofia Bulgaria
Department of Cardiology Shupyk's National Medical Academy of Postgraduate Education Kiev Ukraine
Department of Heart Failure and Valve Disease Skane University Hospital Lund Sweden
Department of Internal Medicine Ghent University Belgium
Department of Public Health Ghent University Ghent Belgium
Institut Pasteur de Lille Université de Lille France
University Hospital Centre Zagreb School of Medicine University of Zagreb Zagreb Croatia
University of Latvia Pauls Stradins Clinical University Hospital Riga Latvia
References provided by Crossref.org